Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ: NUTX), today announced fourth quarter and fiscal year 2025 financial results for the twelve months ended December 31, 2025. Nutex Health is ...
Reported positive top-line data from Phase 2a proof-of-concept (POC) trial of EVO301 in atopic dermatitis (AD)– EVO756 on track to report Phase 2b top-line data in chronic spontaneous urticaria (CSU) ...
Green Thumb Industries Inc. is downgraded from Buy to Hold due to the delay in cannabis rescheduling. Learn more about GTBIF ...
Lojas Renner S.A. announces its results for the fourth quarter and full year 2025 (4Q25 and 2025). All amounts are expressed in millions of Reais and comparisons are with the same period in the ...
Reports $13.2 million in Revenue in the Fourth Quarter, $45.2 million for Full-Year of 2025, Representing increases of 60% and 53%, respectively, Versus the Prior Year PeriodsReaffirms 2026 Revenue ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results